Document is current
Any future updates will be listed below
-
Authors
Dwibedi, Chinmay https://orcid.org/0000-0001-6416-4440
Axelsson, Annika S.
Abrahamsson, Birgitta
Fahey, Jed W.
Asplund, Olof
Hansson, Ola
Ahlqvist, Emma
Tremaroli, Valentina https://orcid.org/0000-0002-9150-4233
Bäckhed, Fredrik
Rosengren, Anders H. https://orcid.org/0000-0002-9333-5736
-
Funding
Funding for this research was provided by:
Knut och Alice Wallenbergs Stiftelse
Vetenskapsrådet (2018-05973)
- License Information
-
More Information
Article History
Received: 23 November 2023
Accepted: 13 January 2025
First Online: 10 February 2025
Competing interests
: A.S.A. and A.H.R. are inventors on patent applications (SE1251306-5, US9,597,307B2 and EU2919775) that cover the use of sulforaphane to treat exaggerated hepatic glucose production. The rights to use this patent have been licensed to Optisan AB. A.H.R. owns stock in Optisan AB. Lantmännen AB provided the BSE and placebo for the study, and Lantmännen Research Fund co-financed the study. V.T. is shareholder and founder of Roxbiosens Inc. F.B. receives research funding from Biogaia AB, is shareholder and founder of Implexion Pharma AB and Roxbiosens Inc, and is on the scientific advisory board of Bactolife A/S. J.W.F. is a co-founder and consultant to Brassica Protection Products, which makes a sulforaphane-producing plant extract for the supplement industry. However, this company was not involved in the present study. The other authors declare no competing interests. This academic investigation was sponsored by the University of Gothenburg, and Optisan AB or Lantmännen AB had no influence on the study procedures, data analysis or interpretation of the data in the paper.
